ArticleBMC complementary medicine and therapies2025
Chemical profile of Ficus lyrata bark extract and its therapeutic effect on non-alcoholic fatty liver disease via regulating oxidative stress, inflammation and hepatic lipogenesis.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide necessitates the attention and intervention of modern medical treatment options. Preliminary studies have demonstrated that Ficus Lyrata leaves can exert protective effects in rats against hepatic fibrosis and hypercholesterolemia. Hence, this study was conducted to investigate the therapeutic effect of Ficus lyrata Wrab bark extract on the NAFLD rat model. NAFLD was induced through a high-fat diet (HFD) for 12 weeks in male Wistar rats. After four weeks of HFD feeding, the rats were treated with F. lyrata extract (250 mg/kg, 5 days/week) or simvastatin (4 mg/kg, 5 days/week) while continuing on the HFD till the end of the experiment. Serum and liver samples were harvested for biochemical, molecular, histopathological, and immunohistochemical investigations. In silico analysis was also conducted to analyse the binding affinity of the extract polyphenols and the key regulators of hepatic lipogenesis. The results revealed that F. lyrata extract administered to HFD-fed rats significantly improved the characteristics of NAFLD by reducing hyperglycemia, hyperinsulinemia, and aminotransferases while improving serum lipid profile and adipokines. Moreover, the extract reduced the expression of hepatic lipogenic genes sterol regulatory element-binding protein-1c (SREBP-1c), acetyl-CoA carboxylase-1 (ACC-1), and fatty acid synthase (FAS), and inflammatory markers tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6), along with modulating oxidative stress markers and reversing histopathological changes. Molecular docking study revealed that most polyphenolic compounds in F. lyrata extract exhibited good binding affinity towards peroxisome proliferator-activated receptors γ (PPAR-γ) and liver X receptor α (LXR-α). In conclusion, our findings suggested that F. lyrata bark could be a promising therapeutic agent against the health issues related to NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.